SecBot SecBot
8-K ·Filed Nov 9, 2026

TTRX

Turn Therapeutics Inc.
NEUTRAL
Impact 4/10
Horizonmonths Processed7d 17h ago SEC0001213900-26-117180
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

The key catalyst is the Phase 2b atopic dermatitis topline data expected in Q1 2027. Cash runway into Q3 2027 provides a buffer, but the company will likely need additional financing before then. Monitor enrollment updates and any early efficacy signals from the ongoing Phase 2b trial.

DirectionNeutral
Confidencehigh
Horizonmonths

GX-03

▲ Bullish Named in this 8-K
Impact
Phase
Phase 2
Time to market
~3-4 years if Phase 2 succeeds; GX-03 needs Phase 3 trials (estimated $55-60M R&D spend per company guidance) and FDA approval. Cash runway only through Q1-Q3 2027, so additional financing likely needed.
Next catalyst
None dated

What to watchGX-03 Phase 2 topline data in Q4 2026 is the next binary inflection point. Interim data (June 2026) showed strong efficacy signals (92.6% EASI-50, 70.4% EASI-75, 44.4% EASI-90 at week 4) with zero serious adverse events. The expanded Stage 2 (~120-135 patients) and planned FDA Type-B meeting make Q4 the key catalyst window. Monitor enrollment updates and any competitive landscape shifts from approved topicals (ruxolitinib, roflumilast).

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5
Entry
$9.79
T+0 close · Nov 9, 2026 · via day close
Latest settled
−12.67%
T+5 · $8.55
Vs SPY
−10.97%
α at T+5
Next horizon
T+20
in 21d
  1. T+0 · Nov 9 $9.79entry
  2. T+1 · 7d ago +1.33%α +1.70% · $9.92
  3. T+5 · 17h ago −12.67%α −10.97% · $8.55
  4. T+20 · in 21d Pending
  5. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Turn Therapeutics reported a net loss of $6.2M for Q3 2026, wider than the $1.9M loss in Q3 2025, driven by a $3.3M non-cash derivative liability charge. The company highlighted positive Phase 2a data for GX-03 in atopic dermatitis and accelerated its HS trial, but remains a pre-revenue clinical-stage biotech with $10.4M cash funding operations into Q3 2027.

Key Financial Metrics

EPS
−$0.21

Key Facts

  • Net loss for Q3 2026 was $6.2M ($0.21 per share) vs $1.9M ($0.07) in Q3 2025
  • Cash and cash equivalents of $10.4M as of September 30, 2026, expected to fund operations into Q3 2027
  • GX-03 Phase 2a atopic dermatitis trial: 59.3% of patients achieved clear/almost clear skin at 4 weeks vs 30.4% vehicle
  • Phase 2b atopic dermatitis trial ongoing, topline results expected Q1 2027
  • Hidradenitis suppurativa Phase 2a trial accelerated, enrollment to begin Q1 2027
  • Robert R. Redfield, M.D., appointed Chief Scientific Officer on September 9, 2026
  • R&D expenses increased to $0.6M from $0.2M year-over-year
  • G&A expenses decreased to $1.4M from $1.8M year-over-year
  • Net loss included $3.3M non-cash charge from change in fair value of derivative liability

Financial Impact

Net loss of $6.2M in Q3 2026, compared to $1.9M in Q3 2025; cash burn rate increased with R&D spending

net losscash and cash equivalentsR&D expenses

Risk Factors

  • Pre-revenue clinical-stage company with no approved products or revenue stream
  • Cash runway only into Q3 2027; additional capital likely needed to complete development
  • Phase 2b atopic dermatitis trial results may not replicate Phase 2a findings
  • Significant non-cash derivative liability charges may continue to impact reported losses
  • Clinical-stage biotech with high volatility and binary trial risk

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
78% bullish (9 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001213900-26-117180
Document: ea0311399-8k_turn.htm0001213900-26-117180
Document: 0001213900-26-117180-index-headers.html0001213900-26-117180
Document: 0001213900-26-117180-index.html0001213900-26-117180
Document: 0001213900-26-117180.txt0001213900-26-117180
8-K Data (Synthetic)0001213900-26-117180

Track record

19 reports on TTRX

Performance horizon

5 of 6 bullish or bearish reports moved the stock their way by T+60. Best: +115.10% at T+60 after the May 18, 2026 report. 8 of 9 went positive at some point.

Filters
  1. Nov 16, 2026today 424B5 Bearish 5/10 Entry $8.55 Now $8.55 −0.00% settles Feb 16
  2. Nov 10, 20266d ago 8-K Neutral 4/10 Entry $9.92 Now $8.55 −13.81% settles Feb 8
  3. Nov 9, 20267d ago S-3 Bearish 6/10 Entry $9.79 Now $8.55 +12.67% settles Feb 5
  4. Nov 9, 20267d ago S-3 Bearish 6/10 Entry $9.79 Now $8.55 +12.67% settles Feb 5
  5. Nov 9, 20267d ago 8-K Neutral 4/10 Viewing Entry $9.79 Now $8.55 −12.67% settles Feb 5
  6. Oct 19, 202628d ago DEF 14A Neutral 3/10 Entry $10.47 Now $8.55 −18.34% settles Jan 15
  7. Oct 6, 20265w ago 8-K Neutral 5/10 Entry $12.10 Now $8.55 −29.34% settles Jan 4
  8. Sep 10, 20269w ago 8-K Neutral 3/10 Entry $13.38 Now $8.55 −36.10% settles Dec 4
  9. Sep 9, 20269w ago 8-K Bullish 5/10 Entry $13.75 Now $8.55 −37.82% settles Dec 3
  10. Aug 18, 202612w ago 8-K Neutral 4/10 Entry $9.99 to $9.92 Now $8.55 −14.41% ▼ −0.70% +1.34% vs SPY
Showing 10 of 19

US Market Status

Market Closed · Opens in 9h 3m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 9, 2026